Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lowe

Showing results (361-370 of 378) with videos related to

Pageof 38
Sort By:
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Prehospital Emergency Care|November 4, 2021
Impact of Prehospital Pain Management on Emergency Department Management of Injured ChildrenM I Harris, K M Adelgais, S W Linakis, et al.
Frontiers in Cardiovascular Medicine|January 27, 2023
MITEA: A dataset for machine learning segmentation of the left ventricle in 3D echocardiography using subject-specific labels from cardiac magnetic resonance imagingDebbie Zhao, Edward Ferdian, Gonzalo D Maso Talou, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Pageof 38

Showing results (361-370 of 378) with videos related to

Sort By:
Pageof 38
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Prehospital Emergency Care|November 4, 2021
Impact of Prehospital Pain Management on Emergency Department Management of Injured ChildrenM I Harris, K M Adelgais, S W Linakis, et al.
Frontiers in Cardiovascular Medicine|January 27, 2023
MITEA: A dataset for machine learning segmentation of the left ventricle in 3D echocardiography using subject-specific labels from cardiac magnetic resonance imagingDebbie Zhao, Edward Ferdian, Gonzalo D Maso Talou, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Pageof 38